Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- 3 Top-Ranked Consumer ETFs to Buy Now
- This Week's Top Value Stocks
- RTI: When Will We Finally See a Pullback?
- RTI: When is the Fed's "Taper Telegraph" Coming?
- Insurance Industry Stock Outlook - May 2013
- Top Stocks with Big Potential Catch-Up Moves
- Roundtable Top Picks of the Week
- The Mega-Rally Rolls On
- Biotechnology ETF Investing 101
- AWS 5/22: Will Bernanke Show His Hand?
- PFP 5/22: Singular Stock Focus Continues
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/22/2013
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 13.16% |
| A M R CP | AAMRQ | 8.66% |
| SCIENTIFIC L | SCIL | 8.00% |
| OLD SECOND B | OSBC | 6.16% |
| MAXWELL TECH | MXWL | 5.12% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Roche Holdings Ltd. ( RHHBY ) recently announced its intension to present results from thirteen studies conducted with pipeline candidates as well as approved products at the upcoming European Society for Medical Oncology (ESMO) Congress.
Roche will be presenting additional data, including overall survival (OS) data, from its phase III EMILIA study. The study compared trastuzumab emtansine (T-DM1) to Xeloda along with lapatinib in HER2-positive unresectable locally advanced or metastatic breast cancer patients who were previously treated with Herceptin and taxane chemotherapy. We note that the study met both the co-primary endpoints of longer progression free survival (PFS) and OS.
The company will also present data from the phase III HERA (HERceptin Adjuvant) study. The study evaluated Herceptin’s impact on disease free survival in women suffering from HER2-positive early breast cancer after completing standard chemotherapy.
Apart from HER2-positive breast cancer treatments, Roche is looking to present data on skin cancer candidates. Data presentation will include results from a pilot study conducted with 24 patients suffering from BRAF V600 mutation-positive metastatic melanoma and symptomatic brain metastases treated with Zelboraf. We note that Zelboraf is already approved in the US and Switzerland to treat patients suffering from inoperable or metastatic melanoma.
Earlier this moth, Roche provided an update on its research and development (R&D) programs and its strategy on innovation for unmet medical needs. The company is expected to present results from 19 late-stage clinical trials in the next 18 months.
Of these, 12 studies are investigating new molecular entities (NMEs). Moreover, Roche expects three additional NMEs to reach the Lifecycle Investment Point (LIP) and move to late-stage development by year end. Roche allotted half of its R&D budget to its oncology segment.
Moreover, Roche implemented rigorous portfolio prioritisation, new development designs, and cost-saving initiatives to keep its R&D budget stable despite its significant pipeline progress.
Our Recommendation
Roche, headquartered in Basel, Switzerland, carries a Zacks #3 Rank (Hold rating) in the short run.
Read the full on RHHBY